Drugs / ROR1 CAR-specific Autologous T-Lymphocytes
ROR1 CAR-specific Autologous T-Lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02706392 | Mar 2016 → May 2021 | B-cell chronic lymphocytic leukemia, mantle cell lymphoma, non-small cell lung carcinoma, triple-negative breast carcinoma | Fred Hutchinson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROR1 CAR-specific Autologous T-Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02706392 ↗ |
| Action | Deplete | “so they specifically may kill cancer cells with a protein called ROR1 on their surfaces” NCT02706392 ↗ |
| Modality | Cell therapy | “autologous T-cells engineered to express a ROR1-specific chimeric antigen receptor (ROR1 CAR-T cells)” PMID 36873868 ↗ Feb 2023 |
| Route | Intravenous | “Given IV” NCT02706392 ↗ |